A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

personalized cancer vaccine, researchers reported Feb. 5. The small, phase 1 trial was carried out by the Dana-Farber Cancer Institute, with the results published in Nature on Wednesday.

A collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging ...

Nine patients with advanced kidney cancer who received an experimental vaccine tailored to their tumors’ specific mutations mounted an immune response to their disease and remained cancer-free ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

Harnessing AI to Revolutionize Vaccine and Therapy Development ATLANTA, GA - (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX ...

An exciting collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging artificial intelligence (AI) to aid the development of T cell ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" used by the nine ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults.